Identifying Pharmaceutical-Grade Essential Oils and Using Them Safely and Effectively in Integrative Medicine
Aruna Bakhru in Nutrition and Integrative Medicine, 2018
Essential oils can be administered orally, which allows for greater precision in dosing, increased convenience, and good bioavailability. Oral administration may also increase the risk of drug interactions and gastrointestinal complaints, and may decrease absorption due to degradation by stomach acid and enzymes when administered in liquids as opposed to capsules. The preferred oral delivery method for essential oils is in a capsule to improve compound dispersion and reduce side effects. A pH-dependent (delayed release) or enteric coated capsule is even better. The risk of gastrointestinal complaints can be reduced if the essential oil capsules are taken with food and a full glass of water. Eructation is commonly reported after oral administration, but it is usually mild and not serious.
The spectrum of voice disorders – classification
Stephanie Martin in Working with Voice Disorders, 2020
Aerophagia has been described as the initial presenting symptom of anxiety and depression in a patient (Appleby and Rosenburg, 2006). It is usually defined as a condition where a person swallows too much air, too frequently, in too large quantities which results in constant and/or excessive belching or burping. The swallowed air goes into the stomach and/or oesophagus and may or may not be associated with digestive upset. It is often thought to be associated with food allergies and GORD. Modification of eating patterns and respiratory intervention has been very successful when working with patients. However, a study of 79 patients with aerophagia and 121 patients with upper gastrointestinal symptoms reports distinctly different symptoms in the two groups (Chitkara et al., 2005), with the patients with aerophagia having an average duration of the disorder of 24 months.
In-clinic procedures
Declan Costello, Guri Sandhu in Practical Laryngology, 2015
Ideally, an in-clinic procedure will start with a calm and relaxed patient who has been well informed regarding the upcoming procedure. The informed consent process serves to satisfy ethical and legal requirements for ensuring patient autonomy and participation in their medical care. It also has the benefit of mentally preparing the patient for the procedure. For instance, if the patient knows ahead of time that during the oesophagoscopy they may experience eructation, oesophageal gas and some gagging, they may be better prepared to tolerate these admittedly unpleasant sensations with less drama. In the authors’ practice, the patient is informed about what to expect at the time of booking the appointment for the procedure, and provided with a short one-page information sheet on what to expect. The day of the procedure, a signed informed consent is obtained, the procedure is explained again and, finally, the preparation for the procedure takes place.
Left lower quadrant pain: an unlikely diagnosis in a case of acute abdomen
Published in Journal of Community Hospital Internal Medicine Perspectives, 2018
Jennifer Williams, Shumona Ima, Charles Milrod, Mahesh Krishnamurthy
A 77-year-old male with a past medical history significant for hypertension and coronary artery disease status post stent placement 3 years ago presented with acute LLQ pain. His medications included Aspirin, Famotidine, Metoprolol, Niacin and Pravastatin. He presented with a 2–3 month history of progressive abdominal distension, a palpable mass on his mid to lower left abdomen, and a sensation of a pulled abdominal muscle. He described associated indigestion with burping, constipation, nausea, anorexia with an unintentional 16lb weight loss, and night sweats. Two days prior to admission the patient felt a sharp, localized pain in his left lower quadrant that did not radiate and was progressively more painful especially when palpated, which he rated as a 7/10 in severity. He described tea colored urine intermittently over the last few months. He denied any fever, chills, sick contacts, recent travel, vomiting, diarrhea, swollen glands or lumps and had a negative history for atrial fibrillation, clotting incidents, or bleeding.
The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial
Published in Gut Microbes, 2022
Sean M. Garvey, Eunice Mah, Traci M. Blonquist, Valerie N. Kaden, Jessica L. Spears
Gastrointestinal (GI) symptoms such as abdominal bloating are commonly reported in otherwise healthy adults, most often in females, and are more severe in those with digestive diseases and functional GI disorders (FGIDs).1,2 In the 2015 National GI Survey of 71,812 community-dwelling adults in the United States inclusive of comorbid conditions, 61% of respondents reported having at least one of eight specific GI symptoms over the prior week.3 The top three reported symptoms were heartburn/reflux (31%), abdominal pain (25%), and bloat/gas (21%). Consistent with these results, in a 1997 survey of 2,510 adults, 41% reported having at least one symptom of abdominal pain or discomfort (22%), bloating or distension (16%), or loose stools or diarrhea (27%) over the prior month.4 Among those respondents with bloating or distension, more than 50% reported a reduction in usual daily activities and 43% took medications such as antacids and anti-gas medications.4 A separate 2003 bloating-specific survey of 2,259 adults suggested the prevalence of abdominal bloating to be 27% overall and 19% when adjusted for the age and sex of the 2000 United States population.5 Abdominal bloating and symptoms related to gas – flatulence and burping – thus represent a significant burden that impacts quality of life in the general population.4 Furthermore, there remains a paucity of interventional trials aiming to reduce gas-related symptoms such as abdominal bloating and flatulence in healthy participants without FGID.
Treatment recommendations for small gastric gastrointestinal stromal tumors: positive endoscopic resection
Published in Scandinavian Journal of Gastroenterology, 2019
Lanping Zhu, Samiullah Khan, Yangyang Hui, Jingwen Zhao, Bianxia Li, Shuang Ma, Junyi Guo, Xin Chen, Bangmao Wang
The baseline information is shown in Table 2. Total 250 patients were enrolled on the basis of meeting criteria for the diagnosis of small gastric GISTs, including 74 men and 176 women, and the ratio of male to female was 1:2.38. The average age was 58.10 ± 9.28 years (range: 29–79). Overall, 217 cases (86.8%) presented with gastrointestinal symptoms before resection, including epigastric pain (89 cases, 35.6%), abdominal bloating (71 cases, 28.4%), epigastric discomfort (55 cases, 22.0%), regurgitation (38 cases, 15.2%), heartburn (30 cases, 12.0%), nausea and vomiting (16 cases, 6.4%), and eructation (14 cases, 5.6%). The remaining 33 cases were asymptomatic, and the tumors were incidentally found. On the basis of the EUS, pathology, and operative reports, 195 tumors were located in the gastric fundus, 43 tumors in the gastric body, and 12 tumors in the gastric antrum. All tumors were originated from the muscularis propria. Besides, 122 out of 250 cases (48.8%) had adverse factors under EUS, mainly including strong echo and heterogeneity. The tumor diameters ranged from 0.2 cm to 2 cm with an average of 1.03 ± 0.47 cm. Immunohistochemical analyses revealed that 96.0% were CD117 positive, 97.6% were CD34 positive, and 99.0% were DOG-1 positive. There were 47 cases which were lacking Dog-1 staining results, so the number of re-enrolled cases was 203. All patients had less than 5 mitotic figures per 50 high-power fields, and 5 patients had a positive staining (>5%) for Ki-67.
Related Knowledge Centers
- Aerophagia
- Carbon Dioxide
- Gastrointestinal Tract
- Hearing
- Mouth
- Oxygen
- Esophagus
- Nitrogen
- Stomach
- Methane Emissions